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Low-level Viremia Persists for at Least 7 years in Patients on Suppressive Antiretroviral Therapy
Results
Background
Persistent viremia can be detected in most HIV-1 infected patients on antiretroviral therapy despite suppression of plasma RNA to <50 copies/ml. Our previous studies have shown diverse antiretroviral regimens suppress plasma viremia to a new setpoint that correlates with pretherapy viremia 1 . These studies could not detect a significant decline in the viremia setpoint over 60-110 weeks of therapy (Figure 1 ). The current analysis assesses plasma HIV-1 RNA levels in subjects on suppressive therapy for 7 years, using a real-time RT-PCR assay with single copy sensitivity.
Assay
An internally controlled real-time RT-PCR assay with single-copy sensitivity (single-copy assay, SCA) 2 was used to test all samples.
Based on sample volumes available in this study, the lower limit of assay sensitivity ranged from 0.4 to 1.0 copies/mL.
Study Entry Criteria
In Study 720, antiretroviral-naive subjects received lopinavir/ritonavir (400/100 mg twice daily) with stavudine and lamivudine twice daily for up to 7 years. Based on all data from weeks 96-360, a statistically significant decrease in plasma HIV-1 RNA level was observed (half-life=239 weeks, p=0.003, Figure 4) . However, when data from week 96 were excluded, no decrease in plasma HIV-1 RNA over time was observed (half-life=971 weeks, p=0.53, Figure  5 ).
Subjects
The distributions of individual subject slopes based on all data and on data from weeks 144-360 are displayed in Figure 6 .
Pre-therapy plasma HIV-1 RNA levels were significantly associated with week 96 levels (p=0.002) and week 252 levels (p=0.005) but not with levels at other timepoints (Figure 7) .
No evidence of a change in plasma HIV-1 RNA values was observed in 18 subjects who replaced stavudine with tenofovir DF.
Median value immediately prior to the switch was 1.37 copies/mL, compared to 1.33 copies/mL 12-24 weeks after the switch (p=0.82, 1-sample t test). On-study samples were tested yearly from week 96 to week 360 (up to 6 samples per subject).
Linear mixed effects regression models were used to assess plasma HIV-1 RNA values over time.
Between year 6 and year 7, subjects were allowed to switch from stavudine to tenofovir DF 3 . Primary analyses described above excluded values after switch to tenofovir; secondary analyses assessed changes in HIV-1 RNA values after the switch to tenofovir using a 1-sample t test. 
Conclusions
